Drugs / Sevirumab
Sevirumab
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00002016 | — | HIV infectious disease, cytomegalovirus retinitis | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00002268 | — | HIV infectious disease, cytomegalovirus infection | Sandoz | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00004642 | Feb 1995 → ? | cytomegalovirus infection | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00000836 | ? → Aug 1998 | HIV infectious disease, cytomegalovirus retinitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00001061 | ? → Mar 1998 | HIV infectious disease, cytomegalovirus retinitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00000135 | Sep 1995 → Aug 1996 | HIV infectious disease, cytomegalovirus retinitis | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sevirumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000836 ↗ |
| Known as | EV2-7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108881 ↗ |
| Known as | MOAB MSL-109 | “OBJECTIVES: I. Evaluate the safety, tolerance, and potential efficacy of 3 doses of human anti-cytomegalovirus (CMV) monoclonal antibody SDZ MSL-109 (MOAB MSL-109) in the...” NCT00004642 ↗ |
| Known as | MSL 109 | “To compare the safety and efficacy of sevirumab (MSL 109; Protovir), human anti-cytomegalovirus (CMV) monoclonal antibody, plus active primary treatment versus placebo plus...” NCT00000836 ↗ |
| Known as | Protovir | “To compare the safety and efficacy of sevirumab (MSL 109; Protovir), human anti-cytomegalovirus (CMV) monoclonal antibody, plus active primary treatment versus placebo plus...” NCT00000836 ↗ |
| Known as | SDZ MSL-109 | “OBJECTIVES: I. Evaluate the safety, tolerance, and potential efficacy of 3 doses of human anti-cytomegalovirus (CMV) monoclonal antibody SDZ MSL-109 (MOAB MSL-109) in the...” NCT00004642 ↗ |
| Modality | Monoclonal antibody | “human anti-cytomegalovirus (CMV) monoclonal antibody” NCT00000836 ↗ |
| Route | Intravenous | “MSL-109, 60 mg intravenously every 2 weeks” PMID 9400786 ↗ Dec 1997 |